Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced the first successful ...

As the first-of-its-kind multi-application platform powered by NPS technology delivering nano-second pulses of electrical energy to non-thermally clear cells while protecting adjacent non-cellular ...

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced ...

Company’s proprietary system used to treat initial five patients in first-in-human feasibility study for patients with atrial fibrillation HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc.

Pulse Biosciences has enrolled the first patient and completed the initial procedure in its NANOCLAMP AF Study, using its newly FDA-cleared nPulse Cardiac Surgical System to treat atrial fibrillation.

Pulse Biosciences, Inc, a novel bioelectric medicine company committed to health innovation and leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology, has ...

Pulse Biosciences announced today that the FDA granted investigational device exemption (IDE) for a pulsed field ablation (PFA) study.

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced positive clinical ...

HAYWARD, Calif., September 02, 2025--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™ ...

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced that the first ...